ERYTECH Pharma S.A. (NASDAQ:ERYP)
Industry: Healthcare

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Current Quote*
Last: $5.100
Change: 1.000
Book: $0.440
Volume: 5,474

As Of: 10/17 13:03 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol ERYP

  • No BuyIns.Net Alerts Available for ERYP

Graphs for ERYP


3 Month Graph


6 Month Graph


1 Year Graph